Companion Diagnostics Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Companion Diagnostics Market

Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Global Forecast to 2029

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 5463 Apr, 2024, by marketsandmarkets.com

The global size of companion diagnostics market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

In recent years, there has been a rapid advancement in medical technology, leading to significant changes in therapies and medicine. This progress has contributed to the substantial growth of the companion diagnostics market. Factors such as the increasing importance of companion diagnostics in drug development, the rising prevalence of cancer, and the growing adoption of targeted therapies are driving the growth of the market.

Attractive Opportunities in the Companion Diagnostics Industry

Companion Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Companion Diagnostics Market Opportunities

Companion Diagnostics Market Dynamics

Driver: Increasing significance of personalized medicine

Growing awareness of the advantages of personalized medicine is a key factor driving the increasing utilization of companion diagnostics and genomics & proteomics technologies. Companion diagnostic tests, which involve analyzing specific indications for particular drugs in individual patients, are integral to tailored treatment plans for numerous chronic diseases and conditions. These tests empower healthcare providers to make informed clinical decisions and lower the risk of unnecessary adverse events. The shift towards personalized medicine is reshaping healthcare practices, with a focus on delivering more precise and effective treatments. This shift further fuels the demand for companion diagnostics products as they enable healthcare providers to make informed and targeted treatment choices, ultimately improving patient outcomes.

Restraint: High capital investment and low cost-benefit ratio

Substantial capital investments are necessary for the discovery, development, and validation of biomarkers. The significant challenge arises from the high drug attrition rate during clinical trials, where nearly 30% of drugs fail in phase III. This poses substantial financial hurdles for diagnostic manufacturers. Manufacturers must achieve successful phase III clinical trials to obtain approval for in vitro diagnostics (IVD) from regulators, which relies on well-validated biomarker tests. Running clinical trials and meeting rigorous regulatory requirements demand considerable investments, impacting the ability of small companies to develop biomarkers and affecting innovation. Consequently, the companion diagnostics market for biomarker detection is hindered not only by the substantial capital required but also by the low cost-benefit ratio.

Opportunity: Increasing importance of companion diagnostics in drug development

The importance of companion diagnostics in aiding healthcare providers with treatment decisions for patients is steadily growing. The co-development of companion diagnostics alongside therapeutic products has the potential to significantly transform the drug development process and streamline the commercialization of drug candidates. This co-development can lead to the creation of safer drugs with enhanced therapeutic efficacy in a quicker and more cost-effective manner. As the demand rises for high-priced specialist therapies and safer medications, the market for companion diagnostics is poised for substantial growth.

Challenge: The shortage of adequately trained professionals

Companion diagnostic testing is a complex and technical process that requires trained professionals. Proficiency in companion diagnostic technologies is essential for conducting tests accurately. There is a lack of awareness among clinicians about the latest advancements in companion diagnostic tests, creating a gap in operational knowledge for clinical laboratories. Additionally, the reluctance to transition from manual operations to automation poses a challenge for market growth. Many providers struggle to switch from manual or traditional methods to IT-based approaches or may resist the change altogether. Hence, the scarcity of skilled, well-trained, and technically knowledgeable laboratory technicians to operate advanced companion diagnostic products is limiting their widespread adoption, particularly in emerging markets.

The market is highly consolidated. The top players—F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US) -in the market accounted for a combined majority market share in 2020. There is a high degree of competition among the market players. Only major companies can afford high-capital investments as well as the high cost of R&D and manufacturing. This will prevent new entrants from entering this market.

Companion Diagnostics Market Product Manufacturers

In 2023, the assays, kits & reagents segment held the largest portion of the companion diagnostics industry, by product & service

Based on product & service, the companion diagnostics market is divided into assays, kits & reagents, instruments/systems and software & services. In 2023, the assays, kits & reagents segment dominated the companion diagnostics market, primarily attributed to the wide variety of available products and the growing utilization of assays and kits across various therapeutic areas.

In 2023, the PCR segment held the companion diagnostics industry largest market share, by technology

The companion diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies, based on technology. In 2023, the PCR segment captured the highest market share, primarily due to its ease of use and extensive availability of PCR kits & reagents for companion diagnostic testing. Additionally, PCR's growing applications in detecting gene mutants with limited or low allele frequencies further contributed to its dominance in the market.

In 2023, the largest share of the companion diagnostics industry was held by the cancer segment, based on indication

The companion diagnostics market is categorized into cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications. In 2023, the cancer segment held the largest portion of the companion diagnostics market. This is driven by factors such as the increasing role of companion diagnostics in personalized medicine treatments for cancer and the growing significance of biomarkers in cancer diagnosis.

Tissue sample segment accounted for the largest companion diagnostics industry share in 2023, based on sample type

Categorized by sample type, the companion diagnostics market is divided into tissue sample, blood sample and other sample types. In 2023, the tissue sample segment held the largest market share in the companion diagnostics market. Tissue samples are preferred in companion diagnostics because they allow for a direct analysis of the tumor, providing a comprehensive view of genetic mutations and biomarkers, which in turn enables more accurate and personalized treatment decisions.

The pharmaceutical & biotechnology companies and reference laboratories segment accounted for the largest companion diagnostics industry share in 2023, by end user

Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users. The pharmaceutical & biotechnology companies segment dominated the market share in 2023. This was driven by the rising adoption of companion diagnostics due to their growing significance in drug development, as well as the increasing importance placed on companion diagnostic biomarkers.

Companion Diagnostics Market By Region

North America holds the leading position as the largest region for companion diagnostics industry

The global companion diagnostics market is segmented into six major regions—North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC countries. In 2023, North America, particularly the U.S. and Canada, leads the global companion diagnostics market. The region's technological advancement and a high number of product approvals by regulatory authorities, such as the FDA, are driving market growth. For example, in October 2022, F. Hoffmann-La Roche Ltd. received FDA approval for the first companion diagnostic to identify patients with HER2 low metastatic breast cancer.

The major players in this market are F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US) and Abbott (US). These players lead the market because of their extensive product portfolios and wide geographic presence. These dominant market players also have numerous advantages, such as more robust marketing and distribution networks, larger budgets for R&D, and better brand recognition.

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Companion Diagnostics Industry

Report Metric

Details

Market Revenue in 2024

$7.5 billion

Projected Revenue by 2029

$13.6 billion

Revenue Rate

Poised to grow at a CAGR of 12.6%

Market Driver

Increasing significance of personalized medicine

Market Opportunity

Increasing importance of companion diagnostics in drug development

This study categorizes the global companion diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Assays, Kits & Reagents
  • Instruments/systems
  • Software & Services

By Technology

  • Polymerase Chain Reaction
  • Next-generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
  • Other Technologies

By Indication

  • Cancer `
    • Lung Cancer
    • Breast Cancer
    • Blood Cancer
    • Colorectal Cancer
    • Other Cancer Types
  • Neurological Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Other Indications

By Sample Type

  • Tissue Samples
  • Blood Samples
  • Other Sample Types

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • Switzerland
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
  • GCC Countries

Recent Developments of Companion Diagnostics Industry

  • In August 2023, Agilent Technologies, Inc. (US) received European IVDR Certification for Companion Diagnostic Assay.
  • In August 2023, QIAGEN (Netherlands). received FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT (avapritinib) in gastrointestinal stromal tumors.
  • In March 2023, F. Hoffmann-La Roche Ltd (Switzerland) received FDA approval of label expansion for VENTANA PD- L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo.
  • In September 2022, Thermo Fisher Scientific Inc. (US) announced FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers.
  • In January 2021, F. Hoffmann-La Roche Ltd (Switzerland) launched two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 46)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SEGMENTATION 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 RESEARCH LIMITATIONS 
    1.6 MARKET STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 52)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 GROWTH RATE ASSUMPTIONS 
    2.7 LIMITATIONS 
    2.8 RISK ASSESSMENT 
           2.8.1 RISK ASSESSMENT ANALYSIS
    2.9 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 66)
    FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
    FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 71)
    4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2024 VS. 2029 
          FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029
    4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029 
          FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
    4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2024 VS. 2029 
          FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY SAMPLE TYPE, 2024 VS. 2029 
          FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.6 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029 
          FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029
    4.7 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 75)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Ability of CDx tests to reduce healthcare costs and increase efficiency
                    5.2.1.2 Growing focus on targeted therapy
                    5.2.1.3 Rising demand for personalized medicine
                                FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015−2022)
                    5.2.1.4 Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine
                                FIGURE 23 GLOBAL CANCER INCIDENCE (2008−2030)
                                TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0–85+), 2022 VS. 2045
                    5.2.1.5 Growing application areas for companion diagnostics
           5.2.2 RESTRAINTS
                    5.2.2.1 Significant capital investment and low cost-benefit ratio
                    5.2.2.2 High cost of companion diagnostic tests
                    5.2.2.3 Unfavorable reimbursements
                                TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS
                    5.2.2.4 High cost of immunotherapy treatment
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for next-generation sequencing
                                TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS
                    5.2.3.2 Growing significance of companion diagnostics in drug development
                                TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
                    5.2.3.3 Advancements in genomics research and rising clinical trials
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of healthcare professionals
                    5.2.4.2 Limited awareness in emerging markets
    5.3 PRICING ANALYSIS 
          TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS
          TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION
    5.4 PATENT ANALYSIS 
          FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014–DECEMBER 2023)
    5.5 TRADE ANALYSIS 
           5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
                    TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION)
                    TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION)
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES
    5.7 SUPPLY CHAIN ANALYSIS 
          FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
    5.8 ECOSYSTEM ANALYSIS 
          FIGURE 27 ECOSYSTEM MAP
          TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
    5.9 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF BUYERS
           5.9.4 BARGAINING POWER OF SUPPLIERS
           5.9.5 INTENSITY OF COMPETITIVE RIVALRY
    5.10 REGULATORY LANDSCAPE 
           5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.10.2 NORTH AMERICA
                    5.10.2.1 US
                    5.10.2.2 Canada
           5.10.3 EUROPE
                     TABLE 15 EUROPE: CLASSIFICATION OF DEVICES
           5.10.4 ASIA PACIFIC
                    5.10.4.1 China
                    5.10.4.2 Japan
                                 TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.10.4.3 India
           5.10.5 LATIN AMERICA
                    5.10.5.1 Brazil
                    5.10.5.2 Mexico
           5.10.6 MIDDLE EAST
           5.10.7 AFRICA
    5.11 TECHNOLOGY ANALYSIS 
           5.11.1 KEY TECHNOLOGIES
                    5.11.1.1 Polymerase chain reaction (PCR)
                    5.11.1.2 Next-generation sequencing (NGS)
           5.11.2 COMPLIMENTARY TECHNOLOGIES
                    5.11.2.1 In situ hybridization (ISH)
           5.11.3 ADJACENT TECHNOLOGIES
                    5.11.3.1 Immunohistochemistry (IHC)
    5.12 KEY CONFERENCES & EVENTS IN 2024–2025 
           TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.13.1 REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET
                     FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS
                     TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%)
           5.14.2 BUYING CRITERIA
                     FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
                     TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
    5.15 INVESTMENT AND FUNDING SCENARIO 
           FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO
 
6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 104)
    6.1 INTRODUCTION 
          TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
    6.2 ASSAYS, KITS, AND REAGENTS 
           6.2.1 INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
                    TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY
                    TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3 INSTRUMENTS & SYSTEMS 
           6.3.1 LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH
                    TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY
                    TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
    6.4 SOFTWARE & SERVICES 
           6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
                    TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY
                    TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION
                    TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
 
7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 116)
    7.1 INTRODUCTION 
          TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
    7.2 POLYMERASE CHAIN REACTION 
           7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
                    TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
                    TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE
                    TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
    7.3 IN SITU HYBRIDIZATION 
           7.3.1 INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH
                    TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE
                    TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
    7.4 NEXT-GENERATION SEQUENCING 
           7.4.1 ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH
                    TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE
                    TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
    7.5 IMMUNOHISTOCHEMISTRY 
           7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
                    TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE
                    TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
    7.6 OTHER TECHNOLOGIES 
          TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
          TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
 
8 COMPANION DIAGNOSTICS MARKET, BY INDICATION (Page No. - 135)
    8.1 INTRODUCTION 
          TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
    8.2 CANCER 
          TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
          TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
          TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
           8.2.1 LUNG CANCER
                    8.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption
                                TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
                                TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
           8.2.2 BREAST CANCER
                    8.2.2.1 Wide prevalence of breast cancer to boost market growth
                                TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
                                TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
           8.2.3 BLOOD CANCER
                    8.2.3.1 Growing incidence of blood cancer to drive market
                                TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040
                                TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
           8.2.4 COLORECTAL CANCER
                    8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth
                                TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
                                TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
           8.2.5 OTHER CANCERS
                    TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
    8.3 NEUROLOGICAL DISEASES 
           8.3.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
                    TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
    8.4 CARDIOVASCULAR DISEASES 
           8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
                    TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
    8.5 INFECTIOUS DISEASES 
           8.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH
                    TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
    8.6 OTHER INDICATIONS 
          TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
          TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
 
9 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE (Page No. - 166)
    9.1 INTRODUCTION 
          TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
    9.2 TISSUE SAMPLES 
           9.2.1 COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET
                    TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS
                    TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
    9.3 BLOOD SAMPLES 
           9.3.1 LESS INVASIVE METHOD—KEY FACTOR DRIVING ADOPTION
                    TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS
                    TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
    9.4 OTHER SAMPLE TYPES 
          TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS
          TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022–2029 (USD MILLION)
          TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
 
10 COMPANION DIAGNOSTICS MARKET, BY END USER (Page No. - 177)
     10.1 INTRODUCTION 
             TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET
                        TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
     10.3 REFERENCE LABORATORIES 
             10.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
                        TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
     10.4 CONTRACT RESEARCH ORGANIZATIONS 
             10.4.1 RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH
                        TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
     10.5 OTHER END USERS 
             TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
             TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
 
11 COMPANION DIAGNOSTICS MARKET, BY REGION (Page No. - 191)
     11.1 INTRODUCTION 
             TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
     11.2 NORTH AMERICA 
             TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045
             FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
             TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
             TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
             TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
             TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
             TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
             TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.2.1 NORTH AMERICA: RECESSION IMPACT
             11.2.2 US
                        11.2.2.1 Increasing use of companion diagnostics for cancer treatment to boost market growth
                                      TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
                                      TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Increasing government initiatives to drive market
                                      TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
                                      TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.3 EUROPE 
             TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
             TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
             TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
             TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
             TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
             TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.1 EUROPE: RECESSION IMPACT
             11.3.2 GERMANY
                        11.3.2.1 Increasing healthcare expenditure to drive market
                                      TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Growing life science industry and increasing focus on research to propel market
                                      TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.4 SWITZERLAND
                        11.3.4.1 Strong research-oriented pharma industry to support market growth
                                      TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.5 FRANCE
                        11.3.5.1 Increasing government funding for research to support market growth
                                      TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.6 ITALY
                        11.3.6.1 Growing geriatric population in region to drive market
                                      TABLE 221 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 222 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 223 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 224 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 225 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 226 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.7 SPAIN
                        11.3.7.1 Increasing focus on advancement of personalized medicine to drive market growth
                                      TABLE 227 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 228 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 229 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 230 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 231 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 232 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.8 REST OF EUROPE
                        TABLE 233 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                        TABLE 234 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                        TABLE 235 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                        TABLE 236 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 237 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                        TABLE 238 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.4 ASIA PACIFIC 
             FIGURE 33 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
             TABLE 239 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 240 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
             TABLE 241 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
             TABLE 242 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
             TABLE 243 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
             TABLE 244 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
             TABLE 245 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
             11.4.2 CHINA
                        11.4.2.1 Advancements in healthcare facilities to drive market
                                      TABLE 246 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
                                      TABLE 247 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 248 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 249 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 250 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 251 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 252 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.3 JAPAN
                        11.4.3.1 Increasing research initiatives to support market growth
                                      TABLE 253 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
                                      TABLE 254 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 255 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 256 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 257 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 258 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 259 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Increased demand for early cancer diagnosis to fuel market growth
                                      TABLE 260 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
                                      TABLE 261 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 262 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 263 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 264 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 265 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 266 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market
                                      TABLE 267 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 268 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 269 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 270 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 271 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 272 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 273 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                        TABLE 274 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                        TABLE 275 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                        TABLE 276 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 277 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                        TABLE 278 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.5 LATIN AMERICA 
             TABLE 279 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 280 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
             TABLE 281 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
             TABLE 282 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
             TABLE 283 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
             TABLE 284 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
             TABLE 285 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.5.1 LATIN AMERICA: RECESSION IMPACT
             11.5.2 BRAZIL
                        11.5.2.1 Increasing incidence of lifestyle diseases to favor market growth
                                      TABLE 286 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 287 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 288 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 289 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 290 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 291 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Growing medical tourism to fuel demand for companion diagnostics
                                      TABLE 292 MEXICO: NEW CANCER CASES, 2022
                                      TABLE 293 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                                      TABLE 294 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                      TABLE 295 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                                      TABLE 296 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 297 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                                      TABLE 298 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 299 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                        TABLE 300 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                        TABLE 301 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                        TABLE 302 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 303 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                        TABLE 304 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
                        TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                        TABLE 306 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                        TABLE 307 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                        TABLE 308 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 309 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                        TABLE 310 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
     11.7 GCC COUNTRIES 
             11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
                        TABLE 311 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
                        TABLE 312 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
                        TABLE 313 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
                        TABLE 314 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 315 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
                        TABLE 316 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.7.2 GCC COUNTRIES: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 280)
     12.1 INTRODUCTION 
     12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
             TABLE 317 COMPANION DIAGNOSTICS MARKET: STRATEGIES ADOPTED
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS (2019–2023)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
             TABLE 318 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 36 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
             12.5.5 COMPANY FOOTPRINT
                        12.5.5.1 Overall footprint
                                      FIGURE 37 COMPANION DIAGNOSTICS MARKET: OVERALL FOOTPRINT
                        12.5.5.2 Product footprint
                                      TABLE 319 COMPANION DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
                        12.5.5.3 Technology footprint
                                      TABLE 320 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
                        12.5.5.4 Indication footprint
                                      TABLE 321 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
                        12.5.5.5 Regional footprint
                                      TABLE 322 COMPANION DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
     12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 38 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 323 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
                        TABLE 324 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
     12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS 
             FIGURE 39 EV/EBITDA OF KEY VENDORS
             FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
     12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 
             FIGURE 41 PRODUCT/BRAND COMPARATIVE ANALYSIS, BY PARAMETER
             12.8.1 F. HOFFMANN-LA ROCHE LTD.
             12.8.2 AGILENT TECHNOLOGIES, INC.
             12.8.3 QIAGEN
             12.8.4 THERMO FISHER SCIENTIFIC INC.
             12.8.5 ABBOTT
     12.9 COMPETITIVE SCENARIO 
             12.9.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 325 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
             12.9.2 DEALS
                        TABLE 326 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2024
 
13 COMPANY PROFILES (Page No. - 295)
(Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     13.1 KEY PLAYERS 
             13.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 327 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
                        TABLE 328 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 329 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
                        TABLE 330 F. HOFFMANN-LA ROCHE LTD.: DEALS
             13.1.2 AGILENT TECHNOLOGIES, INC.
                        TABLE 331 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
                        TABLE 332 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 333 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS
                        TABLE 334 AGILENT TECHNOLOGIES, INC.: DEALS
             13.1.3 QIAGEN
                        TABLE 335 QIAGEN: COMPANY OVERVIEW
                        FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2023)
                        TABLE 336 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 337 QIAGEN: PRODUCT LAUNCHES & APPROVALS
                        TABLE 338 QIAGEN: DEALS
             13.1.4 THERMO FISHER SCIENTIFIC INC.
                        TABLE 339 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
                        TABLE 340 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 341 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS
                        TABLE 342 THERMO FISHER SCIENTIFIC INC.: DEALS
             13.1.5 ABBOTT
                        TABLE 343 ABBOTT: COMPANY OVERVIEW
                        FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2023)
                        TABLE 344 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
             13.1.6 DANAHER
                        TABLE 345 DANAHER: COMPANY OVERVIEW
                        FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023)
                        TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
             13.1.7 GUARDANT HEALTH
                        TABLE 347 GUARDANT HEALTH: COMPANY OVERVIEW
                        FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
                        TABLE 348 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 349 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS
                        TABLE 350 GUARDANT HEALTH: DEALS
                        TABLE 351 GUARDANT HEALTH: OTHER DEVELOPMENTS
             13.1.8 ILLUMINA, INC.
                        TABLE 352 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
                        TABLE 353 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 354 ILLUMINA, INC.: PRODUCT LAUNCHES
                        TABLE 355 ILLUMINA, INC.: DEALS
             13.1.9 BIOMÉRIEUX
                        TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW
                        FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
                        TABLE 357 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
             13.1.10 ICON PLC
                        TABLE 358 ICON PLC: COMPANY OVERVIEW
                        FIGURE 51 ICON PLC: COMPANY SNAPSHOT (2023)
                        TABLE 359 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
             13.1.11 MYRIAD GENETICS, INC.
                        TABLE 360 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
                        FIGURE 52 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
                        TABLE 361 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 362 MYRIAD GENETICS, INC.: PRODUCT APPROVALS
                        TABLE 363 MYRIAD GENETICS, INC.: DEALS
             13.1.12 SYSMEX CORPORATION
                        TABLE 364 SYSMEX CORPORATION: COMPANY OVERVIEW
                        FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
                        TABLE 365 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 366 SYSMEX CORPORATION: DEALS
                        TABLE 367 SYSMEX CORPORATION: OTHER DEVELOPMENTS
     13.2 OTHER PLAYERS 
             13.2.1 ALMAC GROUP
                        TABLE 368 ALMAC GROUP: COMPANY OVERVIEW
             13.2.2 ARUP LABORATORIES
                        TABLE 369 ARUP LABORATORIES: COMPANY OVERVIEW
             13.2.3 ABNOVA CORPORATION
                        TABLE 370 ABNOVA CORPORATION: COMPANY OVERVIEW
             13.2.4 BIOGENEX
                        TABLE 371 BIOGENEX: COMPANY OVERVIEW
             13.2.5 INVIVOSCRIBE, INC.
                        TABLE 372 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
             13.2.6 ARCHERDX, INC.
                        TABLE 373 ARCHERDX, INC.: COMPANY OVERVIEW
             13.2.7 Q² SOLUTIONS
                        TABLE 374 Q² SOLUTIONS: COMPANY OVERVIEW
             13.2.8 AMOY DIAGNOSTICS CO., LTD.
                        TABLE 375 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
             13.2.9 UNIOGEN
                        TABLE 376 UNIOGEN: COMPANY OVERVIEW
             13.2.10 ASURAGEN, INC.
                        TABLE 377 ASURAGEN, INC.: COMPANY OVERVIEW
             13.2.11 MESO SCALE DIAGNOSTICS, LLC
                        TABLE 378 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW
             13.2.12 CREATIVE BIOLABS
                        TABLE 379 CREATIVE BIOLABS: COMPANY OVERVIEW
             13.2.13 NG BIOTECH
                        TABLE 380 NG BIOTECH: COMPANY OVERVIEW
 
*Details on Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 356)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the companion diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.

The four steps involved in estimating the market size are:

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the companion diagnostics market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the companion diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals, clinics and ambulatory surgery centers (ASCs)) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, Latin America and the GCC Countries. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

The following is a breakdown of the primary respondents:

Companion Diagnostics Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

All major product manufacturers offering various companion diagnostics products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value companion diagnostics market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of companion diagnostics market at the regional and country-level.
  • Relative adoption pattern of each companion diagnostics market among key application segments at the regional and/or country-level.
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Global Companion Diagnostics Market Size: Top-Down Approach

Companion Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the companion diagnostics device industry.

Market Definition

A companion diagnostic (CDx) assay is an in vitro diagnostic device (IVD) that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug. CDx uses technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization. The biomarker assessment enable physicians to identify a specific biomarker that could indicate the patients’ most likely outcome-based combination of therapies or even a specific treatment regimen.

Key Stakeholders

  • Manufacturing Companies of Companion diagnostics and Related Devices
  • Original Equipment Manufacturers
  • Suppliers and Distributors of Electroceutical Devices
  • Healthcare Service Providers
  • Teaching Hospitals and Academic Medical Centers (AMCs)
  • Health Insurance Payers
  • Research and Consulting Firms
  • Medical Research Institutes
  • Healthcare Institutes/Providers (Hospitals, Medical Groups, Physicians’ Practices, Diagnostic Centers, and Outpatient Clinics)
  • Venture Capitalists
  • Community Centers

Report Objectives

  • To define, describe, segment, and forecast the companion diagnostics market by product & service, technology, indication, sample type, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges).
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and GCC countries.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze company developments such as acquisitions, collaborations, partnerships, agreements, and product launches & approvals in the companion diagnostics market
  • To benchmark players within the companion diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Companion diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, the Rest of Latin America, and Middle East & Africa.

Company Profiles

  • Product portfolio matrix for leading market players.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 5463
Published ON
Apr, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback